Hara Takahito, Kouno Jin, Nakamura Kazuyo, Kusaka Masami, Yamaoka Masuo
Pharmacology Research Laboratories I, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka, Japan.
Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
Some mutations of androgen receptor (AR) confer resistance to antiandrogen to prostate cancer (PC) cells. Previously we reported that LNCaP-cxD2 cells established from androgen-dependent LNCaP-FGC PC cells as an antiandrogen bicalutamide-resistant subline harbor W741C/L mutation in the AR gene. In this report, we examined one possible mechanism of the resistance.
Change in the gene expression and the protein levels relevant to mutagenesis in LNCaP-FGC cells during bicalutamide-treatment was assessed. The AR sequence of bicalutamide-resistant LNCaP-cxD2 cells was compared with that of parental LNCaP-FGC cells.
The expression of DNA polymerases (Pol) switched from high-fidelity subset to error-prone subset, and DNA mismatch repair proteins (MMR) were down-regulated. The rate of multiple mutations in the AR gene was higher in LNCaP-cxD2 cells than LNCaP-FGC cells.
These results suggest the hypermutational state might occur in LNCaP-FGC cells during bicalutamide-treatment, which might create the W741C/L mutant AR leading to bicalutamide-resistance.
雄激素受体(AR)的某些突变赋予前列腺癌(PC)细胞抗雄激素能力。此前我们报道,从雄激素依赖的LNCaP-FGC PC细胞建立的LNCaP-cxD2细胞作为抗雄激素比卡鲁胺耐药亚系,其AR基因存在W741C/L突变。在本报告中,我们研究了一种可能的耐药机制。
评估比卡鲁胺处理期间LNCaP-FGC细胞中与诱变相关的基因表达和蛋白质水平的变化。将比卡鲁胺耐药的LNCaP-cxD2细胞的AR序列与亲本LNCaP-FGC细胞的AR序列进行比较。
DNA聚合酶(Pol)的表达从高保真亚群转变为易出错亚群,DNA错配修复蛋白(MMR)下调。LNCaP-cxD2细胞中AR基因的多重突变率高于LNCaP-FGC细胞。
这些结果表明,在比卡鲁胺处理期间,LNCaP-FGC细胞可能会出现高突变状态,这可能产生导致比卡鲁胺耐药的W741C/L突变型AR。